References
- Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by 18F-FDG positron emission tomography (PET). Thorax52, 438–441 (1997).
- Gupta NC, Graeber GM, Rogers JS 2nd, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann. Surg.229, 286–291 (1999).
- Berlangieri SU, Scott AM, Knight SR et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer Eur. J. Cardiothorac. Surg.16, S25–S30 (1999).
- Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer, positron emission tomography. Respiration73(3), 267–276 (2006).
- Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med.348, 2500–2507 (2003).
- Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann. Thorac. Surg.78, 1017–1023 (2004).
- Shim SS, Lee KS, Kim BT et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology236, 1011–1019 (2005).
- De Wever W, Ceyssens S, Mortelmans L et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur. Radiol.17, 467–473 (2007).
- Barnett DB. Assessment of quality of life. Am. J. Cardiol.67, C41–C44 (1991).
- Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost–effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J. Nucl. Med.37, 1428–1436 (1996).
- Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest130, 1791–1795 (2006).
- Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann. Nucl. Med.16, 263–271 (2002).
- Sloka JS, Hollett PD, Mathews M. Cost–effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada. Med. Sci. Monit.10, MT73–MT80 (2004).
- Nguyen VH, Peloquin S, Lacasse Y. Cost–effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. Can. Respir. J.12, 19–25 (2005).
- Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost–effectiveness of [18F]-2-fluoro-deoxy-d-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest125, 1413–1416 (2004).
- Verboom P, van Tinteren H, Hoekstra OS et al. Cost–effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur. J. Nucl. Med. Mol. Imaging30, 1444–1449 (2003).
- Herder GJ, Kramer H, Hoekstra OS et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J. Clin. Oncol.24, 1800–1806 (2006).